Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
SEC Accession No. 0000921895-12-001699
Filing Date
2012-08-16
Accepted
2012-08-16 17:10:40
Documents
1
Effectiveness Date
2012-08-16

Document Format Files

Seq Description Document Type Size
1 dfan14a08511002_08162012.htm DFAN14A 53673
  Complete submission text file 0000921895-12-001699.txt   55497
Mailing Address 12270 WILKINS AVENUE ROCKVILLE MD 20852
Business Address 12270 WILKINS AVENUE ROCKVILLE MD 20852 301-770-3099
NABI BIOPHARMACEUTICALS (Subject) CIK: 0000072444 (see all company filings)

EIN.: 591212264 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DFAN14A | Act: 34 | File No.: 001-35285 | Film No.: 121040662
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 10 EAST 53RD STREET 31ST FLOOR NEW YORK NY 10022
Business Address 10 EAST 53RD STREET 31ST FLOOR NEW YORK NY 10022 212 630 5072
Mangrove Partners Fund, L.P. (Filed by) CIK: 0001486623 (see all company filings)

EIN.: 272067192 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DFAN14A